eligibility_summary
Inclusion: adults ≥18, HLA-A2+, unresectable/metastatic colorectal cancer, progressed on/≤3 mo after standard therapy or not candidates, ECOG 0–1, measurable disease, life expectancy ≥3 mo, not pregnant/use contraception. Exclusion: recent steroids/RT/chemo, persistent ≥G2 tox, prior PD-1/PD-L1/CTLA-4, TAS-102/regorafenib, or EO vaccines, key lab abnormalities, other recent cancer, serious comorbidities/infections, autoimmune, transplant, TB, HIV/HBV/HCV, uncontrolled CNS mets, recent live vaccines, hypersensitivity, immunoactive meds, other investigational therapy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1/2, open-label, first-in-human trial in previously treated unresectable metastatic colorectal cancer. Interventions: EO4010, a microbial-derived peptide therapeutic cancer vaccine (HLA-A2–restricted OncoMimic peptides), alone or with nivolumab (anti–PD-1 IgG4 monoclonal antibody) and/or bevacizumab (anti–VEGF-A IgG1 monoclonal antibody). Mechanisms: EO4010 primes and expands tumor-specific CD8+ T cells via dendritic-cell presentation of HLA-A2–restricted peptides to elicit cytotoxic antitumor immunity. Nivolumab blocks PD-1 on T cells to reverse exhaustion and enhance effector function. Bevacizumab neutralizes VEGF-A to inhibit angiogenesis and may normalize tumor vasculature, improving immune infiltration. Targets/pathways: antigen-presenting cells and cytotoxic T cells, PD-1/PD-L1 checkpoint, and VEGF/VEGFR-driven tumor endothelium/angiogenesis. Trial status: terminated (strategic decision, no safety issue).